Free Trial
NYSE:MTNB

Matinas Biopharma (MTNB) Stock Price, News & Analysis

Matinas Biopharma logo
$0.60 +0.01 (+1.71%)
As of 04/24/2025 03:59 PM Eastern

About Matinas Biopharma Stock (NYSE:MTNB)

Key Stats

Today's Range
$0.57
$0.60
50-Day Range
$0.51
$0.64
52-Week Range
$0.47
$9.72
Volume
19,587 shs
Average Volume
182,099 shs
Market Capitalization
$3.03 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Hold

Company Overview

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. It engages in the business of delivering groundbreaking therapies using lipid nanocrystal platform delivery technology to maximize global clinical impact and patient access. The company was founded by Herbert J. Conrad and Jerome D. Jabbour in May 2013 and is headquartered in Bedminster, NJ.

Receive MTNB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Matinas Biopharma and its competitors with MarketBeat's FREE daily newsletter.

MTNB Stock News Headlines

Matinas BioPharma files to sell 16.9M shares of common stock for holders
Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
Matinas BioPharma appoints Murphy, Neugeboren to board of directors
See More Headlines

MTNB Stock Analysis - Frequently Asked Questions

Matinas Biopharma's stock was trading at $0.51 at the beginning of 2025. Since then, MTNB shares have increased by 16.7% and is now trading at $0.5950.
View the best growth stocks for 2025 here
.

Matinas Biopharma Holdings, Inc. (NYSE:MTNB) announced its earnings results on Wednesday, August, 14th. The company reported ($0.02) earnings per share for the quarter, meeting the consensus estimate of ($0.02).

Shares of MTNB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Matinas Biopharma investors own include AcelRx Pharmaceuticals (ACRX), DURECT (DRRX), Kosmos Energy (KOS), Strongbridge Biopharma (SBBP), Selecta Biosciences (SELB), Acasti Pharma (ACST) and Abeona Therapeutics (ABEO).

Company Calendar

Last Earnings
8/14/2024
Today
4/25/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:MTNB
Previous Symbol
NYSE:MTNB
Web
N/A
Fax
N/A
Employees
30
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-22,940,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.10 million
Price / Cash Flow
N/A
Book Value
$4.43 per share
Price / Book
0.13

Miscellaneous

Free Float
4,599,000
Market Cap
$3.03 million
Optionable
N/A
Beta
1.36
10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

This page (NYSE:MTNB) was last updated on 4/25/2025 by MarketBeat.com Staff
From Our Partners